MEIP: MEI Pharma Inc Average Forecast Price

The daily price action for MEI Pharma, Inc. (MEIP) shown on this chart reflects a current value of 22.77. The business relies on its scientific authority gained through the development of cutting-edge methods for combating hematologic malignancies. However, the organization is currently undergoing a wind-down and shareholder payout phase following failed trials, as confirmed by the SEC. Global conflicts further complicate the situation, hindering raw material logistics and patent protection.

MEI Pharma Corporation (MEIP): Price Target Chart from 07/04/2022 to 09/11/2025

Analytical breakdowns for MEI Pharma Corp (MEIP)

- market price and analyst price targets:

Stock Quotes meipharma.com|MEIP - Analyst Consensus Forecast

- market capitalization information:

Market Value MEI Pharma Corp|MEIP - Enterprise Value

- shareholders' equity book value data:

Net Assets per Share MEI Pharma|MEIP - Company Book Value|Market Capitalization to Net Assets meipharma.com|MEIP - Company Total Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

MEIP - Company Net Income|Expected Net Income MEI Pharma, Inc.|MEIP - Price to Earnings Ratio|Future Price to Earnings Multiple MEI Pharma Inc|MEIP - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MEI Pharma Corp|MEIP - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months MEI Pharma|MEIP - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months meipharma.com|MEIP - Earnings per share growth in current year|Expected net earnings per share growth next year MEI Pharma, Inc.

Fundamental company analysis:meipharma.com (MEIP)

The colossal scaling potential of MEI Pharma, Inc. (MEIP) in hematologic oncology directly drives changes in the consensus valuation of the stock, reflecting market expectations for the global rollout of its drugs. This indicator represents an aggregated discounted cash flow model, where analysts continuously recalculate the cost of capital to determine the fair market value of the company's assets.

Competing companies